By Fineline Cube 
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has submitted a new indication application to the National Medical Products Administration (NMPA) for its Category 1 product candidate jacktinib in severe alopecia areata. The application has been accepted for review.
Drug Profile and Mechanism
Jacktinib is a Janus kinase (JAK) inhibitor that demonstrates significant inhibitory effects on JAK1, JAK2, JAK3, and TYK2, with particularly strong inhibition of JAK2 and TYK2. This mechanism of action positions jacktinib as a promising therapeutic option for conditions involving abnormal immune responses.
Clinical Development
In addition to the new indication filing for severe alopecia areata, jacktinib is also undergoing marketing review in China for the treatment of medium to high-risk myelofibrosis. This broader development program underscores Zelgen’s commitment to leveraging jacktinib’s potential across multiple therapeutic areas.-Fineline Info & Tech